following a full submission:
abemaciclib (Verzenios®) is accepted for use within NHSScotland.
Indication under review: for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor* as initial endocrine-based therapy, or in women who have received prior endocrine therapy.
In a phase III randomised study in women with HR-positive, HER2-negative advanced breast cancer, abemaciclib in combination with an aromatase inhibitor significantly increased progression-free survival compared with aromatase inhibitor monotherapy.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of abemaciclib. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.
*For SMC advice relating to the use of abemaciclib in combination with fulvestrant in this setting, please refer to SMC2179.
To read more Press Release articles, click here.